Bavarian Nordic A/S (OTC Pink - Limited Information:BVNKF)

34.25
Delayed Data
As of May 20
 +1.88 / +5.81%
Today’s Change
16.76
Today|||52-Week Range
56.50
-17.47%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$1.3B

Company Description

Bavarian Nordic A/S focuses on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. It specializes in cancer immunotherapy which includes cancer pipeline, which focuses on therapeutic vaccines for breast, lung, ovarian and prostate cancer. Its products include IMVAMUNE for Ebola, HPV, HBV, and HIV diseases. The company was founded in 1994 and is headquartered in Kvistgaard, Denmark.

Contact Information

Bavarian Nordic A/S
Hejreskovvej 10A
Kvistgaard Capital Region 3490
P:(453) 326-8383
Investor Relations:
(456) 177-4743

Employees

Shareholders

Mutual fund holders--
Individual stakeholders--
Other institutional--

Top Executives

Paul ChaplinPresident & Chief Executive Officer
Russell ThirskChief Operating Officer & Executive Vice President
Henrik Neilsen JuuelChief Financial Officer & Executive Vice President
Laurence de MoerloozeChief Medical Officer & Executive Vice President
Anu Helena KernsChief People Officer & Executive Vice President